<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745498</url>
  </required_header>
  <id_info>
    <org_study_id>B-0801-053-004</org_study_id>
    <nct_id>NCT00745498</nct_id>
  </id_info>
  <brief_title>Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy</brief_title>
  <acronym>IBDV</acronym>
  <official_title>Efficacy Study of Pre- and Intra-operative Intravitreal Bevacizumab Injection on Postoperative Vitreous Hemorrhage After Diabetic Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab
      injection on postoperative vitreous hemorrhage after diabetic vitrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative vitreous hemorrhage(VH) is a common complication after vitrectomy for
      proliferative diabetic retinopathy. Persistent or recurrent VH can delay visual
      rehabilitation and give patients much trouble. There have been efforts to lower the incidence
      of postoperative VH such as using intraoperative gas tamponade and preoperative bevacizumab
      injection. Bevacizumab(Avastin) is a potent inhibitor of angiogenesis and has been shown to
      decrease retinal and iris neovascularization in proliferative diabetic retinopathy. Recently
      there have been reports showing that preoperative intravitreal bevacizumab (IVB) injection
      could reduce intraoperative bleeding from abnormal vessels and could make surgery easier and
      more successful.Our hypothesis is that preoperative bevacizumab injection could reduce
      postoperative VH by way of decreasing the amount of abnormal vessels and intraoperative
      injection could also reduce postoperative VH by inhibiting the vessel formation after
      surgery.

      To prove our hypothesis, we started the prospective randomized comparative study to determine
      the effect of pre- and intra-operative IVB injection on postoperative vitreous hemorrhage
      after diabetic vitrectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent VH Incidence (Early and Late)</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrent VH was defined as a new episode of grade 1 or more VH occurring more than 1 week after surgery. &quot;Early recurrent VH&quot; was VH occurring &lt;= 4 weeks and &quot;late recurrent VH&quot; was VH occurring &gt;4 weeks after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial Time of Vitreous Clearing (ITVC)</measure>
    <time_frame>6 months</time_frame>
    <description>The interval in number of days for VH of grade 1 or more observed at postoperative day 1 to clear-up completely. VH of grade 1 was defined as mild vitreous hemorrhage with visible fundus details, but difficult to evaluate the retinal nerve fiber layer or small vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Best-corrected visual acuity (BCVA) at postoperative 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Resolution of Neovascularization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Vitreous Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Preop IVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraop IVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No IVB</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)</description>
    <arm_group_label>Preop IVB</arm_group_label>
    <arm_group_label>Intraop IVB</arm_group_label>
    <other_name>avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing first vitrectomy for complications of proliferative diabetic
             retinopathy such as vitreous hemorrhage, tractional fibrovascular membrane
             proliferation, tractional or combined retinal detachment)

        Exclusion Criteria:

          -  Follow-up period of less than 6 months

          -  Intraoperative use of long-acting gas or silicone oil

          -  Repeat vitrectomy after first vitrectomy for diseases other than vitreous hemorrhage

          -  Not first vitrectomy

          -  Uncontrolled hypertension

          -  Medical history of abnormal blood coagulation

          -  Time interval between IVB injection and PPV longer than 2 weeks and recent history
             (within 3 months) of IVB treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu Hyung Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National Univeristy Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyunggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006 Jul-Aug;26(6):699-700.</citation>
    <PMID>16829817</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>November 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2015</results_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Kyu Hyung Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Proliferative diabetic retinopathy</keyword>
  <keyword>vitrectomy</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>vitreous hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive diabetic patients requiring pars plana vitrectomy (PPV) for complications of diabetic retinopathy at Seoul National University Bundang Hospital were referred to assess eligibility.</recruitment_details>
      <pre_assignment_details>If indications for PPV included proliferative diabetic retinopathy (PDR) related complications such as nonclearing vitreous hemorrhage (VH), macula-involving or â€“threatening tractional retinal detachment (TRD) or fibrovascular proliferation with vitreoretinal adhesions, the patient was enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Preop IVB</title>
          <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 7 days before vitrectomy</description>
        </group>
        <group group_id="P2">
          <title>Introp IVB</title>
          <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
        </group>
        <group group_id="P3">
          <title>No IVB</title>
          <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Injection of intravitreal silicone oil o</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-PDR related VH</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Edophthalmitis after preoperative IVB</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preop IVB</title>
          <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 7 days before vitrectomy</description>
        </group>
        <group group_id="B2">
          <title>Intraop IVB</title>
          <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
        </group>
        <group group_id="B3">
          <title>No IVB</title>
          <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="9.5"/>
                    <measurement group_id="B2" value="55.6" spread="10.3"/>
                    <measurement group_id="B3" value="55.0" spread="11.4"/>
                    <measurement group_id="B4" value="53.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrent VH Incidence (Early and Late)</title>
        <description>Recurrent VH was defined as a new episode of grade 1 or more VH occurring more than 1 week after surgery. &quot;Early recurrent VH&quot; was VH occurring &lt;= 4 weeks and &quot;late recurrent VH&quot; was VH occurring &gt;4 weeks after surgery.</description>
        <time_frame>6 months</time_frame>
        <population>With study power of 80%, significance level of 0.05, assumption that IVB injection will decrease postoperative VH incidence from 35% to 10%, a sample size of 40 patients for each group was calculated. The ITT approach was used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Preop IVB</title>
            <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 7 days before vitrectomy</description>
          </group>
          <group group_id="O2">
            <title>Intraop IVB</title>
            <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
          </group>
          <group group_id="O3">
            <title>No IVB</title>
            <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent VH Incidence (Early and Late)</title>
          <description>Recurrent VH was defined as a new episode of grade 1 or more VH occurring more than 1 week after surgery. &quot;Early recurrent VH&quot; was VH occurring &lt;= 4 weeks and &quot;late recurrent VH&quot; was VH occurring &gt;4 weeks after surgery.</description>
          <population>With study power of 80%, significance level of 0.05, assumption that IVB injection will decrease postoperative VH incidence from 35% to 10%, a sample size of 40 patients for each group was calculated. The ITT approach was used for analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With study power of 80%, a significance level of 0.05, and the assumption that IVB injection will decrease postoperative VH incidence from 35% to 10%, a sample size of 40 patients for each group was calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Time of Vitreous Clearing (ITVC)</title>
        <description>The interval in number of days for VH of grade 1 or more observed at postoperative day 1 to clear-up completely. VH of grade 1 was defined as mild vitreous hemorrhage with visible fundus details, but difficult to evaluate the retinal nerve fiber layer or small vessels.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preop IVB</title>
            <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 7 days before vitrectomy</description>
          </group>
          <group group_id="O2">
            <title>Intraop IVB</title>
            <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
          </group>
          <group group_id="O3">
            <title>No IVB</title>
            <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Time of Vitreous Clearing (ITVC)</title>
          <description>The interval in number of days for VH of grade 1 or more observed at postoperative day 1 to clear-up completely. VH of grade 1 was defined as mild vitreous hemorrhage with visible fundus details, but difficult to evaluate the retinal nerve fiber layer or small vessels.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="42.5"/>
                    <measurement group_id="O2" value="10.3" spread="8.2"/>
                    <measurement group_id="O3" value="25.2" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Outcome</title>
        <description>Best-corrected visual acuity (BCVA) at postoperative 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preop IVB</title>
            <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 7 days before vitrectomy</description>
          </group>
          <group group_id="O2">
            <title>Intraop IVB</title>
            <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
          </group>
          <group group_id="O3">
            <title>No IVB</title>
            <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Outcome</title>
          <description>Best-corrected visual acuity (BCVA) at postoperative 6 months</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.58"/>
                    <measurement group_id="O2" value="0.68" spread="0.47"/>
                    <measurement group_id="O3" value="0.51" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Resolution of Neovascularization</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Preop IVB</title>
          <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 7 days before vitrectomy</description>
        </group>
        <group group_id="E2">
          <title>Intraop IVB</title>
          <description>Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy</description>
        </group>
        <group group_id="E3">
          <title>No IVB</title>
          <description>Patients will not receive bevacizumab before nor during vitrectomy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Rhegmatogenous retinal detachment immediately following operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>neovascular glaucoma following surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Se Joon Woo</name_or_title>
      <organization>Seoul National University Bundang Hospital Department of Ophthalmology</organization>
      <phone>+82-31-787-7377</phone>
      <email>sejoon1@hanmail.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

